Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How does Olipudase Alfa treat ASMD?

How does olipudase alfa work in ASMD?

Olipudase alfa (also known by the brand name Xenpozyme) is an enzyme replacement therapy designed for acid sphingomyelinase deficiency (ASMD, also called Niemann-Pick disease type A/B spectrum). It works by providing a functional version of the missing enzyme, acid sphingomyelinase, which helps the body break down sphingomyelin, a fatty substance that builds up in lysosomes in people with ASMD. By increasing sphingomyelin breakdown, it reduces lysosomal storage and the related organ damage driven by that buildup [1].

What changes in the body when the enzyme replaces the missing activity?

By restoring acid sphingomyelinase activity, olipudase alfa helps lower the amount of accumulated sphingomyelin in affected tissues. That reduction in storage is intended to translate into clinical improvements seen in ASMD, particularly in aspects of disease burden related to organ involvement (for example, spleen and liver enlargement) [1].

What is the goal of treatment for ASMD (and what does it target)?

The treatment goal with olipudase alfa is to address the underlying enzyme deficiency that drives sphingomyelin accumulation, rather than only treating symptoms. In practice, that means targeting the root cause of lysosomal storage so that tissue and organ pathology linked to sphingomyelin buildup can improve or slow [1].

How is olipudase alfa given, and how does that affect treatment expectations?

Olipudase alfa is administered as an infusion. Like other enzyme replacement therapies, dosing is designed to maintain enough enzyme activity in the body over time to support ongoing sphingomyelin breakdown [1].

How does this differ from other ASMD management approaches?

Because olipudase alfa is a replacement for the missing enzyme activity, it differs from supportive care approaches (such as monitoring and symptom-directed management). It is the disease-modifying strategy aimed at correcting the metabolic defect that leads to sphingomyelin storage [1].

Sources
[1] https://www.drugpatentwatch.com/



Other Questions About Olipudase :

How does olipudase alfa treat niemann pick?